MedTrace Logo

Measurement of Platelet Dense Granule Release in Healthy Volunteers

NCT00942617 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-12-07

No results posted yet for this study

Summary

Aspirin has been shown to reduce cardiovascular events in at risk individuals. Elucidation of mechanisms of aspirin resistance and a possible loss of effect of aspirin over time with chronic aspirin treatment necessitate a more precise method of measuring the "release phase" of platelet activation, including the release of dense granules from platelets.

Conditions

  • Platelet Aggregation

Interventions

DRUG

Aspirin

40 mg non-enteric coated ASA once daily for 21 + or - 2 days

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • John A Oates, M.D. · Vanderbilt University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00942617 on ClinicalTrials.gov